Arovella Therapeutics Limited
ALA.ASXHealth Care
A biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform for cancer treatment.
Market Data
$0.071
+0.0%$85.8M
-100000.0x
$-0.007
0.00%
-0.3%
Latest Earnings
Half Year Report and Appendix 4D
19 February 2026
Arovella Therapeutics reported a 29% increase in loss to $1.88M for HY2026, despite receiving $3.2M in R&D tax incentives. The company achieved a major milestone with FDA acceptance of its IND application for ALA-101 and maintains a strong cash position of $19.4M. Key points: FDA accepted IND application for ALA-101, enabling first-in-human clinical trials; Completed all IND-enabling manufacturing and non-clinical activities for lead asset; Strong cash position of $19.4M providing runway for Phase 1 clinical trial
Recent Announcements
Half Year Report and Appendix 4D
Arovella Therapeutics reported a 29% increase in loss to $1.88M for HY2026, despite receiving $3.2M in R&D tax incentives. The company achieved a major milestone with FDA acceptance of its IND application for ALA-101 and maintains a strong cash position of $19.4M. Key points: FDA accepted IND application for ALA-101, enabling first-in-human clinical trials; Completed all IND-enabling manufacturing and non-clinical activities for lead asset; Strong cash position of $19.4M providing runway for Phase 1 clinical trial
Get real-time alerts for ALA
Receive AI-powered earnings summaries and instant notifications when Arovella Therapeutics Limited releases results.
Register Free